1 / 11

Mark A. Watson, Arie Perry, and David H. Gutmann Washington University School of Medicine

Molecular analysis of sporadic and neurofibromatosis 1 (NF1)-associated malignant peripheral nerve sheath tumors. Mark A. Watson, Arie Perry, and David H. Gutmann Washington University School of Medicine

alima
Download Presentation

Mark A. Watson, Arie Perry, and David H. Gutmann Washington University School of Medicine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Molecular analysis of sporadic and neurofibromatosis 1 (NF1)-associated malignant peripheral nerve sheath tumors Mark A. Watson, Arie Perry, and David H. Gutmann Washington University School of Medicine *Supported by funding from the Department of Defense and Washington University/Siteman Cancer Center

  2. MPNST • Devastating tumor • Poor response to therapy • Poor patient survival • Patients with neurofibromatosis 1 (NF1) harbor 10% lifetime risk of developing MPNST

  3. NF1 loss seen in 76% MPNST by FISH • Neurofibromin loss seen in 9/9 MPNST NF1 inactivation is critical event in MPNST pathogenesis

  4. p16 deletion in MPNSTs Tumorp16 deletionp16 HD Schwannoma 0/5 0/5 Plexiform neurofibroma 0/13 0/13 MPNST 16/20 9/20 (75%) (45%) Synovial sarcoma 5/7 0/7 (71%) Fibrosarcoma 5/6 0/6 (83%) Hemangiopericytoma 8/12 0/12 (67%) CEP9 p16 J. Neuropath Exp. Neurol., 2002

  5. Benign Neurofibromas Malignant Peripheral Nerve Sheath Tumors DG102 DG206 WU33 1570 2157 5628 6218 6696 8235 MB 511 KL DP 19 EGF-R EGFR amplification in MPNSTs CEP7 EGFR TumorEGF-R amplification Schwannoma 0/5 Plexiform neurofibroma 0/13 MPNST 5/19 (26%) Synovial sarcoma 0/7 Fibrosarcoma 0/6 Hemangiopericytoma 0/13 J. Neuropath Exp. Neurol., 2002

  6. Gene expression profiling 25 NF1-associated 17 sporadic tumors Genetic signature to distinguish NF1-associated from sporadic? Genetic signature to predict clinical behavior?

  7. 4247 4263 4260 4236 4252 4261424042744262425742414258 4238 4239 4276 42704235 4244 4266 42694251423042644271 4232 4242 4245 423142554234425342334254423742564265424342594246425042484275424942684267 SIAT9 MGLL GCM1 SGCE SEC14L1 DDX21 SSSSSSSSSsnssSsnsnNnnnNnnnsNNnsNsnnNNnnnNNnNn Few, if any, gene expression signatures that distinguish between NF1-associated and sporadic MPNSTs

  8. EGFR Expression Sporadic (n=17) NF1 (n=25) EGFR(-) EGFR(+)

  9. Group A NCAM, MBP, L1CAM, PLP1, BLBP, GAP43, APO-D, RELN IGF2, FGFR1, MDK, CCNB1, CCNB2, CCNF, Ki67 EGFR(-) “more differentiated phenotype”

  10. Conclusions • NF1 loss is observed in both NF1-associated and sporadic MPNST • CDKN2A inactivation is frequently observed in MPNST • EGFR amplification is observed in one-third MPNST • Expression profiling did not identify a molecular fingerprint that distinguishes NF1-associated from sporadic MPNST • Expression profiling identified a molecular fingerprint for a subset of more aggressive MPNSTs • Expression profiling identified a molecular fingerprint for a subset of MPNST with a more differentiated phenotype • Future prospective studies will be required to determine whether these patterns of gene expression predict clinical behavior

More Related